Lv21
130 积分 2022-11-21 加入
Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression
9个月前
已完结
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
1年前
已完结
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial
1年前
已完结
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?
1年前
已完结
Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature
1年前
已完结
A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications
1年前
已完结
A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications
1年前
已关闭
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
1年前
已完结
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
1年前
已完结
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
1年前
已完结
皖公网安备34019202002308
